Medications

The Janus kinase inhibitor baricitinib has the potential to be “an important part of the treatment landscape” for juvenile arthritis, research suggests.

Infliximab appears efficacious for patients with juvenile-onset spondyloarthritis who have failed to respond to conventional treatment, phase 3 study findings show.

Click through for further information on this expanded indication

Click through for more information

Click through for further details on this announcement

Autoantibodies against IL-1Ra are present in a large proportion of patients with MIS-C, say researchers.

Withdrawing therapy on the basis of low levels of high-sensitivity C-reactive protein and the calcium-binding protein S100A12 may be a feasible approach for young people with juvenile idiopathic arthritis in remission, PREVENT-JIA study data show.

Click through for additional details

Exposure to tumor necrosis factor inhibitors is associated with a threefold increased risk for developing psoriasis in children with juvenile idiopathic arthritis, US study findings indicate.

The Pfizer–BioNTech vaccine against SARS-CoV-2 is well tolerated and does not cause disease flares in young people with juvenile idiopathic arthritis treated with TNF inhibitors, suggest findings from a small study.

In a chart review of patients with childhood-onset rheumatic diseases treated with rituximab, over a quarter developed hypogammaglobulinemia and a similar proportion had infectious complications, researchers report.

Rituximab is well tolerated and shows good efficacy in children with granulomatosis with polyangiitis or microscopic polyangiitis, global phase 2a study findings indicate.

Click through for more information on this announcement

Children and adolescents with juvenile psoriatic arthritis or enthesitis-related arthritis may benefit from treatment with the IL-17A inhibitor secukinumab, indicate phase 3 study results.

Researchers have found that children and young people with juvenile idiopathic arthritis can be categorized into five different groups according to their response to etanercept treatment.